New hope for older aplastic anemia patients: drug combo may prevent transplant rejection
NCT ID NCT06752694
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 32 times
Summary
This study tests whether adding ruxolitinib to standard medications can prevent graft-versus-host disease (GVHD) in adults over 40 receiving a stem cell transplant for aplastic anemia, a condition where the bone marrow fails to produce enough blood cells. GVHD occurs when donor immune cells attack the recipient's body. The trial involves one participant and aims to see if this approach reduces severe GVHD compared to past results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APLASTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.